First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.

Michael Untch; Michael Muscholl; Sergei Tjulandin; Walter Jonat; Hans-Gerd Meerpohl; Mikhail Lichinitser; Alexey G Manikhas; Alexandra Coumbos; Rolf Kreienberg; Andreas du Bois; Nadia Harbeck; Christian Jackisch; Volkmar Müller; Matthias Pauschinger; Christoph Thomssen; Michaela Lehle; Olivier Catalani; Hans-Joachim Lück

doi:10.1200/JCO.2009.21.9709

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.

Michael Untch
, Michael Muscholl
, Sergei Tjulandin
, Walter Jonat
, Hans-Gerd Meerpohl
, Mikhail Lichinitser
, Alexey G Manikhas
, Alexandra Coumbos
, Rolf Kreienberg
, Andreas du Bois
, Nadia Harbeck
, Christian Jackisch
, Volkmar Müller
, Matthias Pauschinger
, Christoph Thomssen
, Michaela Lehle
, Olivier Catalani
, Hans-Joachim Lück

Universitätsklinik für Innere Medizin 8 - Kardiologie

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

56 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	1473-1480
Fachzeitschrift	JOURNAL OF CLINICAL ONCOLOGY
Jahrgang	28
Ausgabenummer	9
DOIs	https://doi.org/10.1200/JCO.2009.21.9709
Publikationsstatus	Veröffentlicht - 2010

Zugriff auf Dokument

10.1200/JCO.2009.21.9709

Dieses zitieren

Untch, M., Muscholl, M., Tjulandin, S., Jonat, W., Meerpohl, H.-G., Lichinitser, M., Manikhas, A. G., Coumbos, A., Kreienberg, R., du Bois, A., Harbeck, N., Jackisch, C., Müller, V., Pauschinger, M., Thomssen, C., Lehle, M., Catalani, O., & Lück, H.-J. (2010). First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. JOURNAL OF CLINICAL ONCOLOGY , 28(9), 1473-1480. https://doi.org/10.1200/JCO.2009.21.9709

Untch, Michael ; Muscholl, Michael ; Tjulandin, Sergei et al. / First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. in: JOURNAL OF CLINICAL ONCOLOGY 2010 ; Jahrgang 28, Nr. 9. S. 1473-1480.

@article{59976ed2facb46918d56c24263ab737d,

title = "First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.",

keywords = "PEGYLATED LIPOSOMAL DOXORUBICIN, PHASE-II TRIAL, NEOADJUVANT THERAPY, CHEMOTHERAPY, PACLITAXEL, ANTHRACYCLINES, 5-FLUOROURACIL, AMPLIFICATION, HER-2/NEU, SURVIVAL",

author = "Michael Untch and Michael Muscholl and Sergei Tjulandin and Walter Jonat and Hans-Gerd Meerpohl and Mikhail Lichinitser and Manikhas, \{Alexey G\} and Alexandra Coumbos and Rolf Kreienberg and \{du Bois\}, Andreas and Nadia Harbeck and Christian Jackisch and Volkmar M{\"u}ller and Matthias Pauschinger and Christoph Thomssen and Michaela Lehle and Olivier Catalani and Hans-Joachim L{\"u}ck",

year = "2010",

doi = "10.1200/JCO.2009.21.9709",

language = "English",

volume = "28",

pages = "1473--1480",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins ",

number = "9",

}

Untch, M, Muscholl, M, Tjulandin, S, Jonat, W, Meerpohl, H-G, Lichinitser, M, Manikhas, AG, Coumbos, A, Kreienberg, R, du Bois, A, Harbeck, N, Jackisch, C, Müller, V, Pauschinger, M, Thomssen, C, Lehle, M, Catalani, O & Lück, H-J 2010, 'First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.', JOURNAL OF CLINICAL ONCOLOGY , Jg. 28, Nr. 9, S. 1473-1480. https://doi.org/10.1200/JCO.2009.21.9709

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. / Untch, Michael; Muscholl, Michael; Tjulandin, Sergei et al.
in: JOURNAL OF CLINICAL ONCOLOGY , Jahrgang 28, Nr. 9, 2010, S. 1473-1480.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

TY - JOUR

T1 - First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.

AU - Untch, Michael

AU - Muscholl, Michael

AU - Tjulandin, Sergei

AU - Jonat, Walter

AU - Meerpohl, Hans-Gerd

AU - Lichinitser, Mikhail

AU - Manikhas, Alexey G

AU - Coumbos, Alexandra

AU - Kreienberg, Rolf

AU - du Bois, Andreas

AU - Harbeck, Nadia

AU - Jackisch, Christian

AU - Müller, Volkmar

AU - Pauschinger, Matthias

AU - Thomssen, Christoph

AU - Lehle, Michaela

AU - Catalani, Olivier

AU - Lück, Hans-Joachim

PY - 2010

Y1 - 2010

KW - PEGYLATED LIPOSOMAL DOXORUBICIN

KW - PHASE-II TRIAL

KW - NEOADJUVANT THERAPY

KW - CHEMOTHERAPY

KW - PACLITAXEL

KW - ANTHRACYCLINES

KW - 5-FLUOROURACIL

KW - AMPLIFICATION

KW - HER-2/NEU

KW - SURVIVAL

U2 - 10.1200/JCO.2009.21.9709

DO - 10.1200/JCO.2009.21.9709

M3 - Original Article

C2 - 20177030

SN - 0732-183X

VL - 28

SP - 1473

EP - 1480

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 9

ER -

Untch M, Muscholl M, Tjulandin S, Jonat W, Meerpohl HG, Lichinitser M et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. JOURNAL OF CLINICAL ONCOLOGY . 2010;28(9):1473-1480. doi: 10.1200/JCO.2009.21.9709